Liermann Jakob, Syed Mustafa, Ben-Josef Edgar, Schubert Kai, Schlampp Ingmar, Sprengel Simon David, Ristau Jonas, Weykamp Fabian, Röhrich Manuel, Koerber Stefan A, Haberkorn Uwe, Debus Juergen, Herfarth Klaus, Giesel Frederik L, Naumann Patrick
Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Cancers (Basel). 2021 Feb 14;13(4):796. doi: 10.3390/cancers13040796.
(1) Background: A new radioactive positron emission tomography (PET) tracer uses inhibitors of fibroblast activation protein (FAPI) to visualize FAP-expressing cancer associated fibroblasts. Significant FAPI-uptake has recently been demonstrated in pancreatic cancer patients. Target volume delineation for radiation therapy still relies on often less precise conventional computed tomography (CT) imaging, especially in locally recurrent pancreatic cancer patients. The need for improvement in precise tumor detection and delineation led us to innovatively use the novel FAPI-PET/CT for radiation treatment planning. (2) Methods: Gross tumor volumes (GTVs) of seven locally recurrent pancreatic cancer cases were contoured by six radiation oncologists. In addition, FAPI-PET/CT was used to automatically delineate tumors. The interobserver variability in target definition was analyzed and FAPI-based automatic GTVs were compared to the manually defined GTVs. (3) Results: Target definition differed significantly between different radiation oncologists with mean dice similarity coefficients (DSCs) between 0.55 and 0.65. There was no significant difference between the volumes of automatic FAPI-GTVs based on the threshold of 2.0 and most of the manually contoured GTVs by radiation oncologists. (4) Conclusion: Due to its high tumor to background contrast, FAPI-PET/CT seems to be a superior imaging modality compared to the current gold standard contrast-enhanced CT in pancreatic cancer. For the first time, we demonstrate how FAPI-PET/CT could facilitate target definition and increases consistency in radiation oncology in pancreatic cancer.
(1)背景:一种新型放射性正电子发射断层扫描(PET)示踪剂利用成纤维细胞活化蛋白(FAPI)抑制剂来可视化表达FAP的癌症相关成纤维细胞。最近在胰腺癌患者中已证实有显著的FAPI摄取。放射治疗的靶区勾画仍常常依赖于不太精确的传统计算机断层扫描(CT)成像,尤其是在局部复发的胰腺癌患者中。对精确肿瘤检测和勾画的改进需求促使我们创新性地将新型FAPI-PET/CT用于放射治疗计划。(2)方法:由六位放射肿瘤学家勾勒出七例局部复发胰腺癌病例的大体肿瘤体积(GTV)。此外,使用FAPI-PET/CT自动勾画肿瘤。分析了观察者间在靶区定义上的变异性,并将基于FAPI的自动GTV与手动定义的GTV进行比较。(3)结果:不同放射肿瘤学家之间的靶区定义存在显著差异,平均骰子相似系数(DSC)在0.55至0.65之间。基于2.0阈值的自动FAPI-GTV体积与放射肿瘤学家手动勾勒的大多数GTV体积之间没有显著差异。(4)结论:由于其高肿瘤与背景对比度,与目前胰腺癌的金标准对比增强CT相比,FAPI-PET/CT似乎是一种更优越的成像方式。我们首次展示了FAPI-PET/CT如何能够促进靶区定义并提高胰腺癌放射肿瘤学中的一致性。